Perceptions of People Who Inject Drugs About Long-acting Medications for Opioid Use Disorder, Preexposure Prophylaxis, and Antiretroviral Therapy
Open Access
- 28 February 2025
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (3) , ofaf120
Abstract
Background: Long-acting injectable (LAI) forms of preexposure prophylaxis and antiretroviral therapy and extended-release medications for opioid use disorder (OUD) may reduce HIV and OUD treatment attrition, but community interest among people who inject drugs remains underexplored. Methods: From September to December 2023, we conducted a cross-sectional survey of adults with OUD and a history of injection drug use who were attending a New Jersey syringe exchange program to assess their experiences with HIV and OUD care and their knowledge, attitudes, and preferences about LAI. Results: Of 193 participants, 15 were persons with HIV (PWH), 72 were high risk for HIV (HRH), and 91 were low risk for HIV (LRH). Many participants had previously taken medications for OUD (60%), but knowledge of extended-release medications for OUD was low (40% PWH, 45.8% HRH, 41.6% LRH, P = .85). Participant interest in extended-release naltrexone (33.3% PWH, 27.8% HRH, 26.7% LRH, P = .91) and extended-release buprenorphine (33.3% PWH, 18.3% HRH, 20.9% LRH, P = .45) was also low. Preexposure prophylaxis knowledge was high (59.1% HRH, 63.9% LRH, P = .54), but prior usage (11.1% HRH, 6.7% LRH, P = .32) and interest (18.1% HRH, 21.1% LRH P = .63) in LAI preexposure prophylaxis were low. PWH had high awareness (66.7%) and interest (66.7%) in receiving LAI antiretroviral therapy. Interest in integrated care was greater for PWH (69.2%) than for those at HRH (29.8%) or LRH (33.9%; P = .03), and preferred treatment locations varied among the groups. Conclusions: Targeted education and outreach are particularly needed for extended-release medications for OUD and LAI preexposure prophylaxis. A differentiated care model may better address the needs of people who inject drugs with OUD, whether at risk for or with HIV. Addressing barriers to LAI treatment remains essential.Keywords
Funding Information
- National Institute on Drug Abuse
- National Institutes of Health (K23DA053989)
This publication has 30 references indexed in Scilit:
- Integrated Care Models: HIV and Substance UseCurrent HIV/AIDS Reports, 2023
- Systematic review of the values and preferences regarding the use of injectable pre‐exposure prophylaxis to prevent HIV acquisitionJournal of the International AIDS Society, 2023
- Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons With Commercial Insurance and Likely Injection Drug UseJAMA Network Open, 2022
- PrEP Care Continuum Engagement Among Persons Who Inject Drugs: Rural and Urban Differences in Stigma and Social InfrastructureAIDS and Behavior, 2021
- HIV Pre-exposure Prophylaxis and Buprenorphine at a Drug Detoxification Center During the Opioid Epidemic: Opportunities and ChallengesAIDS and Behavior, 2021
- Ending the HIV EpidemicJAMA, 2019
- Medications for Treatment of Opioid Use Disorder among Persons Living with HIVCurrent HIV/AIDS Reports, 2019
- Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug UsersAIDS and Behavior, 2017
- Factors Related to Pre-exposure Prophylaxis Prescription by U.S. Primary Care PhysiciansAmerican Journal of Preventive Medicine, 2017
- Primary Care Physicians’ Willingness to Prescribe HIV Pre-exposure Prophylaxis for People who Inject DrugsAIDS and Behavior, 2016